Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.

doi:10.1097/FPC.0000000000000108

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.

Pharmacogenetics and genomics - 1 Feb 2015

Drozda Katarzyna, Wong Shan, Patel Shitalben R, Bress Adam P, Nutescu Edith A, Kittles Rick A, Cavallari Larisa H

Abstract excerpt

OBJECTIVES: Recent clinical trial data cast doubt on the utility of genotype-guided warfarin dosing, specifically showing worse dosing with a pharmacogenetic versus clinical dosing algorithm in African Americans. However, many genotypes important in African Americans were not accounted for. We aimed to determine whether omission of the CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11 alleles and rs12777823 G > A genotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticoagulants

Share to Black or African American

Share to Cytochrome P-450 CYP2C9

Share to Dose-Response Relationship, Drug

Share to Drug Dosage Calculations

Share to Pharmacogenetics

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 25461246
DOI: 10.1097/FPC.0000000000000108
PMCID: PMC4280295

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.PMID 25461246Read ↗

CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic DosingSemantic proximity Read ↗

Warfarin Pharmacogenetics Reevaluated: Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials.Semantic proximity Read ↗

Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.Semantic proximity Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

The future of warfarin pharmacogenetics in under-represented minority groups.Semantic proximity Read ↗

Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.Semantic proximity Read ↗

Genetic and clinical predictors of warfarin dose requirements in African Americans.Semantic proximity Read ↗

STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION.Semantic proximity Read ↗

Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.Semantic proximity Read ↗

A pharmacogenetic versus a clinical algorithm for warfarin dosing.Semantic proximity Read ↗

Warfarin pharmacogenetics: does more accurate dosing benefit patients?Semantic proximity Read ↗

<i>VKORC1</i> Polymorphisms, Haplotypes and Haplotype Groups on Warfarin Dose Among African–Americans and European–AmericansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.